Our RNA characterization and optimization platform provides custom solutions to ensure that RNA therapeutic development succeeds. Contact us today to learn how our team can help you achieve your mRNA goals.
Contact useMERGE
RNA Therapeutic Solutions
eMERGE is the comprehensive platform for RNA characterization and optimization that provides actionable insights into potency, stability, and safety. Discover how we reduce development timelines by providing the data needed for effective vaccines and therapies.
RNA Therapeutics
From developing rapid-response vaccines to personalized cancer treatments, RNA is the future of medicine. However, multiple challenges remain in developing a successful therapeutic including the fine-tuning of cellular regulation, achieving efficient translation, and limiting innate immune responses. We have combined our unique portfolio of cutting-edge capabilities to create the eMERGE platform, the only comprehensive solution for RNA characterization and optimization. Discover how we can help you reduce development risks and reach the clinic with confidence.
Contact usInfectious Disease Vaccines
Cancer Vaccines
Monoclonal Antibodies
Gene Therapies
Protein Replacement Therapies
eMERGE,
the solution for RNA medicine success
To solve the most pressing needs of mRNA, circular RNA, and self-amplifying RNA drug developers we have combined our full portfolio of technologies and designed novel bioinformatics workflows for the eMERGE platform. Our unique platform provides comprehensive views of therapeutic activity from detecting dsRNA sources to measuring the timecourse of therapeutic translation. The results can be used to select optimal UTRs and codons during sequence design and optimization, evaluate manufacturing processes, and deeply characterize lead drug products before clinical trials. For each eMERGE project, our partners meet with our team of RNA experts to determine your needs and the optimal set of experiments and analyses to perform. Scroll below to see some examples of the insights that eMERGE provides.
Contact usActionable insights from validated data
Each eMERGE project is customized to the needs of our partners. The following are some examples of how our platform provides comprehensive characterization and precision optimization of RNA vaccines and therapeutics.
Find optimal codons for increased protein output
Effective translation is critical for RNA efficacy. However, stalls and frameshifts can occur and limit protein output. We use empirical data from target cell types to:
- Select optimal codons that are cell- and tissue-specific without relying on predictions
- Locate ribosome stalls and optimize sequences to improve translation
- Measure translation over time to identify optimal candidates for therapeutic efficacy
Identification of ribosome pause sites along a transfected mRNA
Locate and quantify dsRNA
IVT errors can lead to double-stranded (dsRNA) that activates the innate immune system. However, locating the origin of dsRNA is challenging. We have developed a unique, next-generation sequencing based approach to:
- Quantify dsRNA including lengths below antibody detection limits
- Identify where IVT runoff begins and ends
- Evaluate the effects of different manufacturing optimizations or base changes on dsRNA production
The bottom line plot shows the amount of dsRNA at each base position along an RNA. The two sources of the dsRNA shown in the gray box are indicated by the red lines. The thickness and color of the line indicates the relative contribution of each base position to the generation of the dsRNA by-product.
Determine RNA structure in LNPs and cells
RNA structure is critical for stability. However, computational methods for predicting structure can be inaccurate when predicting structure in the context of LNPs or the cellular environment. With our proprietary approach we:
- Directly measure RNA structure in LNPs
- Evaluate secondary structure in cells
- Determine changes in structure during drug product formulation
RNA structures can change with different LNP formulations, potentially leading to changes in storage stability. Data was generated in partnership with Acuitas Therapeutics.
eMERGE:
the mRNA success platform
Each eMERGE project is customized to meet your needs, discover our typical workflow below.
Contact usDiscuss
Our scientific and project management team meets with you to review your challenges and goals.
Plan
We develop a customized project proposal that is tailored to solve your specific needs.
Analyze
Our team of RNA experts delivers a comprehensive, data-driven report featuring actionable insights.
What our
partners say
"Eclipsebio’s analysis of RNA folding has provided valuable insights necessary to understand the impact of RNA sequence and chemical modifications on secondary structures…to help improve the design of our RNAs and rationalize our internal findings."
"At Acuitas we are interested in how modifications to LNP formulations can impact efficacy and stability. Eclipsebio’s eSHAPE assay has potentially revealed direct correlations between LNP composition and RNA secondary structure, further adding to our understanding of the mechanism of action for RNA-LNP systems."
Need additional support?
At Eclipsebio, we value innovation and are continuously developing new assays for better characterization and optimization of RNA therapeutics. If you would like to gain early access to our newest technologies or if you need a solution that isn’t listed above, contact us today.
Contact usLearn more with our eBlogs
RNA-based therapeutic characterization methods
Before release into the clinic, mRNA therapeutics need comprehensive characterization. In this eBlog, we review key quality attributes of mRNA therapeutics.
mRNA therapeutic design
mRNA therapeutics are revolutionizing medicine, but the design of an effective RNA can be challenging. In this eBlog, we review key design factors for developing a potent and stable therapeutic.
Five reasons RNA-based therapeutics fail
In this eBlog, we discuss why RNA therapeutic development can fail and ways to limit the risk.